Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012, Article ID 804730, 6 pages
http://dx.doi.org/10.1100/2012/804730
Clinical Study

A Prospective Study Evaluating IOP Changes after Switching from a Therapy with Prostaglandin Eye Drops Containing Preservatives to Nonpreserved Tafluprost in Glaucoma Patients

1Eye Clinic, San Giuseppe Hospital, University of Milan, Via San Vittore 12, 20123 Milan, Italy
2Frontier Science & Technology Research Foundation Southern Europe (FSE), 6830 Chiasso, Switzerland
3Data Management Service, Multimedica Group, 20159 Milan, Italy

Received 3 October 2011; Accepted 1 November 2011

Academic Editors: J. Aquavella and I. Lipshitz

Copyright © 2012 Stefano Ranno et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. O. Gordon, J. A. Beiser, J. D. Brandt et al., “The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma,” Archives of Ophthalmology, vol. 120, no. 6, pp. 714–720, 2002. View at Google Scholar · View at Scopus
  2. C. Wesselink, M. W. Markus, and N. M. Jansonius, “Risk factors for visual field progression in the Groningen Longitudinal Glaucoma Study: a comparison of different statistical approaches,” Journal of Glaucoma. In press. View at Publisher · View at Google Scholar
  3. M. C. Leskea, A. Heijl, L. Hyman, B. Bengtsson, and E. Komaroff, “Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial,” Current Opinion in Ophthalmology, vol. 15, no. 2, pp. 102–106, 2004. View at Google Scholar
  4. The AGIS Investigators, “The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration,” American Journal of Ophthalmology, vol. 130, no. 4, pp. 429–440, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. European Glaucoma Society (EGS), Terminology and Guidelines for Glaucoma, Editrice Dogma s.r.l., Savona, Italy, 3rd edition, 2008.
  6. T. Hamacher, J. Airaksinen, V. Saarela, M. J. Liinamaa, U. Richter, and A. Ropo, “Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: Results from a pharmacodynamics analysis,” Acta Ophthalmologica, vol. 86, supplement 242, pp. 14–19, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. C. B. Camras, L. Z. Bito, and K. E. Eakins, “Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits,” Investigative Ophthalmology and Visual Science, vol. 16, no. 12, pp. 1125–1134, 1977. View at Google Scholar · View at Scopus
  8. T. Nakajima, T. Matsugi, W. Goto et al., “New fluoroprostaglandin F2α derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents,” Biological and Pharmaceutical Bulletin, vol. 26, no. 12, pp. 1691–1695, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Ota, M. Aihara, S. Narumiya, and M. Araie, “Effects of protaglandin-analogues on IOP in prostanoid FP receptor deficient mice,” Investigative Ophthalmology & Visual Science, vol. 46, no. 11, pp. 4159–4163, 2005. View at Google Scholar
  10. T. Ota, M. Aihara, S. Narumiya, and M. Araie, “Effects of protaglandin-analogues on IOP in prostanoid FP receptor deficient mice,” Investigative Ophthalmology & Visual Science, vol. 26, no. 12, pp. 1691–1695, 2003. View at Google Scholar
  11. D. J. Oh, J. L. Martin, A. J. Williams, P. Russell, D. E. Birk, and D. J. Rhee, “Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells,” Investigative Ophthalmology and Visual Science, vol. 47, no. 9, pp. 3887–3895, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Ishida, N. Odani-Kawabata, A. Shimazaki, and H. Hara, “Prostanoids in the therapy of glaucoma,” Cardiovascular Drug Reviews, vol. 24, no. 1, pp. 1–10, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. S. F. Nilsson, E. Drecoll, E. Lutjen-Drecoll et al., “The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey,” Investigative Ophthalmology & Visual Science, vol. 47, no. 9, pp. 4042–4049, 2006. View at Google Scholar
  14. M. Aihara, “Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension,” Clinical Ophthalmology, vol. 4, no. 1, pp. 163–170, 2010. View at Google Scholar · View at Scopus
  15. Y. Takagi, T. Nakajima, A. Shimazaki et al., “Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug,” Experimental Eye Research, vol. 78, no. 4, pp. 767–776, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Baudouin, “Side effects of antiglaucomatous drugs on the ocular surface,” Current Opinion in Ophthalmology, vol. 7, no. 2, pp. 80–86, 1996. View at Google Scholar · View at Scopus
  17. J. Shimazaki, K. Hanada, Y. Yagi et al., “Changes in ocular surface caused by antiglaucomatous eyedrops: Prospective, randomised study for the comparison of 0.5% timolol v 0.12% unoprostone,” British Journal of Ophthalmology, vol. 84, no. 11, pp. 1250–1254, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Pozarowska, P. Pozarowski, and Z. Darzynkiewicz, “Cytometric assessment of cytostatic and cytotoxic effects of topical glaucoma medications on human epithelial corneal line cells,” Cytometry Part B - Clinical Cytometry, vol. 78, no. 2, pp. 130–137, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Martone, P. Frezzotti, G. M. Tosi et al., “An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology,” American Journal of Ophthalmology, vol. 147, no. 4, pp. 725–735, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. M. De Saint Jean, C. Debbasch, F. Brignole, P. Rat, J. M. Warnet, and C. Baudouin, “Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells,” Current Eye Research, vol. 20, no. 2, pp. 85–94, 2000. View at Google Scholar · View at Scopus
  21. H. Liang, C. Baudouin, A. Pauly, and F. Brignole-Baudouin, “Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride,” British Journal of Ophthalmology, vol. 92, no. 9, pp. 1275–1282, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Brasnu, F. Brignole-Baudouin, L. Riancho, J. M. Guenoun, J. M. Warnet, and C. Baudouin, “In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line,” Current Eye Research, vol. 33, no. 4, pp. 303–312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Sutton, A. Gilvarry, and A. Ropo, “A comparative, placebo-controlled study of prostanoid fluoroprostaglandin- receptor agonists tafluprost and latanoprost in healthy males,” Journal of Ocular Pharmacology and Therapeutics, vol. 23, no. 4, pp. 359–365, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Ota, H. Murata, E. Sugimoto, M. Aihara, and M. Araie, “Protaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24 hour variation,” Investigative Ophthalmology & Visual Science, vol. 46, no. 6, pp. 2006–2011, 2005. View at Google Scholar
  25. H. Liang, C. Baudouin, A. Pauly, and F. Brignole-Baudouin, “Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride,” British Journal of Ophthalmology, vol. 92, no. 9, pp. 1275–1282, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. Cornea and Contact Lens Research Unit (CCLRU) Grading Scale, University of New South Wales, School of Optometry, Sydney, Australia, 1996.
  27. M. Centofanti, F. Oddone, M. Vetrugno et al., “Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study,” European Journal of Ophthalmology, vol. 19, no. 1, pp. 66–71, 2009. View at Google Scholar · View at Scopus
  28. H. Mochizuki, H. Itakura, T. Yokoyama, M. Takamatsu, and Y. Kiuchi, “Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects,” Japanese Journal of Ophthalmology, vol. 54, no. 4, pp. 286–290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Uusitalo, L. E. Pillunat, and A. Ropo, “Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study,” Acta Ophthalmologica, vol. 88, no. 1, pp. 12–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. C. E. Traverso, A. Ropo, M. Papadia, and H. Uusitalo, “A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost,” Journal of Ocular Pharmacology and Therapeutics, vol. 26, no. 1, pp. 97–104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Hommer, O. Mohammed Ramez, M. Burchert, and F. Kimmich, “IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma,” Current Medical Research and Opinion, vol. 26, no. 8, pp. 1905–1913, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Centofanti, F. Oddone, S. Gandolfi et al., “Comparison of travoprost and bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination,” American Journal of Ophthalmology, vol. 150, no. 4, pp. 575–580, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Uusitalo, E. Chen, N. Pfeiffer et al., “Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication,” Acta Ophthalmologica, vol. 88, no. 3, pp. 329–336, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Schnober, G. Hofmann, H. Maier, M. L. Scherzer, A. B. Ogundele, and M. C. Jasek, “Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension,” Clinical Ophthalmology, vol. 4, no. 1, pp. 1459–1463, 2010. View at Publisher · View at Google Scholar · View at Scopus